In the absence of a submission from the holder of the marketing authorisation, liraglutide (Victoza®) cannot be endorsed for use within NHS Wales for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.